drugset / Trial / NCT07355257
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.
Timeline
- Start
- 2026-02-02
- Primary completion
- 2026-12-30
- Completion
- 2027-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |